Oculis Holding (OCS) said Thursday it priced an underwritten offering of 5 million ordinary shares at $20 apiece, targeting gross proceeds of $100 million.
The company said the "oversubscribed" offering will likely close on or about Feb. 18. The new shares will bring the total number of registered shares to more than 53.9 million before closing.
Oculis intends to use the net proceeds to, among other things, advance and accelerate its clinical development pipeline, particularly its neuroprotective clinical candidate Privosegtor, or OCS-05.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.